Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Adult
Aged
Aged, 80 and over
Antigens, CD
/ analysis
Antigens, Differentiation, Myelomonocytic
/ analysis
Antineoplastic Agents, Immunological
/ therapeutic use
B7-H1 Antigen
/ analysis
Biomarkers, Tumor
/ analysis
CD8 Antigens
/ analysis
Female
Fluorescent Antibody Technique
Forkhead Transcription Factors
/ analysis
Humans
Immune Checkpoint Proteins
/ analysis
Macrophages
/ chemistry
Male
Melanoma
/ chemistry
Middle Aged
Prognosis
Programmed Cell Death 1 Receptor
/ analysis
Progression-Free Survival
Receptors, Cell Surface
/ analysis
SOXE Transcription Factors
/ analysis
Single-Cell Analysis
T-Lymphocyte Subsets
/ chemistry
Treatment Outcome
Tumor Microenvironment
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
11 06 2021
11 06 2021
Historique:
received:
26
11
2019
revised:
08
02
2021
accepted:
03
05
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Next-generation tissue-based biomarkers for immunotherapy will likely include the simultaneous analysis of multiple cell types and their spatial interactions, as well as distinct expression patterns of immunoregulatory molecules. Here, we introduce a comprehensive platform for multispectral imaging and mapping of multiple parameters in tumor tissue sections with high-fidelity single-cell resolution. Image analysis and data handling components were drawn from the field of astronomy. Using this "AstroPath" whole-slide platform and only six markers, we identified key features in pretreatment melanoma specimens that predicted response to anti-programmed cell death-1 (PD-1)-based therapy, including CD163
Identifiants
pubmed: 34112666
pii: 372/6547/eaba2609
doi: 10.1126/science.aba2609
pmc: PMC8709533
mid: NIHMS1764053
pii:
doi:
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD163 antigen
0
CD274 protein, human
0
CD8 Antigens
0
FOXP3 protein, human
0
Forkhead Transcription Factors
0
Immune Checkpoint Proteins
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Receptors, Cell Surface
0
SOX10 protein, human
0
SOXE Transcription Factors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P50 CA121974
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197296
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA142779
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243627
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA196390
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA193145
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA247886
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Sci Rep. 2017 Oct 17;7(1):13380
pubmed: 29042640
J Histochem Cytochem. 2007 Feb;55(2):105-9
pubmed: 16982846
Sci Immunol. 2016 Jul 14;1(1):aaf6925
pubmed: 28783673
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724788
J Immunother Cancer. 2018 Oct 1;6(1):99
pubmed: 30285852
Science. 2012 Nov 30;338(6111):1220-5
pubmed: 23197535
J Immunother Cancer. 2018 Jun 6;6(1):48
pubmed: 29871672
Mod Pathol. 2018 Feb;31(2):214-234
pubmed: 29192647
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15016-21
pubmed: 18809920
Science. 2020 Jan 31;367(6477):
pubmed: 32001626
Nat Immunol. 2019 Nov;20(11):1425-1434
pubmed: 31611702
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Nat Med. 2019 Mar;25(3):470-476
pubmed: 30742120
Cancer Immunol Res. 2018 Apr;6(4):481-493
pubmed: 29467127
Curr Opin Immunol. 2017 Apr;45:73-81
pubmed: 28236750
Clin Cancer Res. 2019 Jun 1;25(11):3455-3467
pubmed: 30808776
Nat Rev Cancer. 2019 Apr;19(4):215-227
pubmed: 30867580
J Immunother Cancer. 2019 Feb 12;7(1):43
pubmed: 30755279
J Immunol. 2018 Jan 1;200(1):347-354
pubmed: 29141863
Immunity. 2019 Jan 15;50(1):181-194.e6
pubmed: 30635236
Cancer Res. 2017 Feb 15;77(4):851-861
pubmed: 27979840
Nat Immunol. 2020 Oct;21(10):1232-1243
pubmed: 32929275
Science. 2001 Sep 14;293(5537):2037-40
pubmed: 11557879
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Sci Transl Med. 2018 Jul 18;10(450):
pubmed: 30021886
Arch Pathol Lab Med. 2014 Nov;138(11):1432-43
pubmed: 24646069
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Med. 2019 Apr;25(4):656-666
pubmed: 30833750
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Int J Cancer. 2011 Aug 1;129(3):636-47
pubmed: 20857491
Curr Opin Pharmacol. 2015 Aug;23:32-8
pubmed: 26047524
Cancer Inform. 2013 Sep 23;12:193-201
pubmed: 24092958
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Nature. 2006 Mar 23;440(7083):413-4
pubmed: 16554783
JAMA Oncol. 2019 Aug 1;5(8):1195-1204
pubmed: 31318407
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Immunother Cancer. 2020 May;8(1):
pubmed: 32414858
Cell. 2019 Oct 31;179(4):846-863.e24
pubmed: 31668803
Clin Cancer Res. 2017 Aug 15;23(16):4938-4944
pubmed: 28428193
Cancer Res. 2010 Nov 1;70(21):8378-87
pubmed: 20861189